MedTrace Logo

A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS

NCT00244244 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2012-02-09

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

arimoclomol

Sponsors & Collaborators

  • CytRx

    lead INDUSTRY

Principal Investigators

  • Merit Cudkowicz, MD · Massachusetts General Hospital

  • Jeremy Shefner, MD · State University of New York - Upstate Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-10-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00244244 on ClinicalTrials.gov